MAIA Biotechnology, Inc. (NYSE: MAIA) completed a $33 million common‑stock offering in March 2026, and the proceeds were announced on April 8, 2026. The capital raise fully funds the company’s pivotal Phase 3 THIO‑104 trial of ateganosine (THIO) in third‑line non‑small cell lung cancer (NSCLC).
The THIO‑104 study is a global, multicenter, open‑label, randomized trial that will enroll up to 300 patients. It compares ateganosine in combination with a checkpoint inhibitor to standard chemotherapy. Ateganosine is a first‑in‑class telomere‑targeting agent that also activates immune responses, and it has received FDA Fast Track designation for third‑line NSCLC.
The $33 million raise eliminates the immediate bankruptcy risk that had surrounded MAIA and provides a cash runway of roughly two years at the company’s current burn rate. MAIA has no debt and a significant cash position, allowing it to focus on executing the Phase 3 program without additional financing pressure.
CEO Vlad Vitoc said, “We are grateful for the support and confidence shown by the healthcare‑dedicated investors and existing shareholders who participated in our recent offering. The $33 million raise is expected to complete the necessary funding for our pivotal Phase 3 trial through completion.” He added, “Statistical assessments point to a high probability of technical success in the third‑line setting if Phase 3 data is consistent with our Phase 2 trial results.”
By fully funding the Phase 3 trial, MAIA removes a major financial hurdle and positions ateganosine for potential regulatory approval. The company’s focus can now shift to trial execution and data collection, with interim results expected next year that may support a discussion with the FDA for early full commercial approval in third‑line NSCLC.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.